Drug Trial Radar · NCT07241416
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
206
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Mar 2027
Study completion Sep 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.
Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Rezvilutamide TabletsDrug
Rezvilutamide tablets, oral administration.
Enzalutamide Soft CapsulesDrug
Enzalutamide soft capsules, oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prostate Specific Antigen (PSA) undetectable rate based on central laboratory.Time frame: 6 months after randomization.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.